{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:00:25Z","timestamp":1790960425018,"version":"4.1.0"},"reference-count":184,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41584-026-01379-1","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:19:28Z","timestamp":1779293968000},"page":"411-428","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment strategies in giant cell arteritis and polymyalgia rheumatica: beyond glucocorticoids"],"prefix":"10.1038","volume":"22","author":[{"given":"Francesco","family":"Muratore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7708-2487","authenticated-orcid":false,"given":"Kenneth J.","family":"Warrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0173-0668","authenticated-orcid":false,"given":"Christian","family":"Dejaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4730-0938","authenticated-orcid":false,"given":"Maria C.","family":"Cid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8014-1801","authenticated-orcid":false,"given":"Bernhard","family":"Hellmich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1109-624X","authenticated-orcid":false,"given":"Ann W.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Croci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3708-3148","authenticated-orcid":false,"given":"Carlo","family":"Salvarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"1379_CR1","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1056\/NEJMra011913","volume":"347","author":"C Salvarani","year":"2002","unstructured":"Salvarani, C., Cantini, F., Boiardi, L. & Hunder, G. G. Polymyalgia rheumatica and giant-cell arteritis. N. Engl. J. Med. 347, 261\u2013271 (2002).","journal-title":"N. Engl. J. Med."},{"key":"1379_CR2","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/s41584-023-00976-8","volume":"19","author":"A Tomelleri","year":"2023","unstructured":"Tomelleri, A. et al. Disease stratification in GCA and PMR: state of the art and future perspectives. Nat. Rev. Rheumatol. 19, 446\u2013459 (2023).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1379_CR3","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.4065\/81.8.1071","volume":"81","author":"GG Hunder","year":"2006","unstructured":"Hunder, G. G. The early history of giant cell arteritis and polymyalgia rheumatica: first descriptions to 1970. Mayo Clin. Proc. 81, 1071\u20131083 (2006).","journal-title":"Mayo Clin. Proc."},{"key":"1379_CR4","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0140-6736(64)92784-9","volume":"1","author":"B Hamrin","year":"1964","unstructured":"Hamrin, B., Jonsson, N. & Landberg, T. Arteritis in \u2018polymyalgia rheumatica\u2019. Lancet 1, 397\u2013401 (1964).","journal-title":"Lancet"},{"key":"1379_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103415","volume":"23","author":"C Salvarani","year":"2024","unstructured":"Salvarani, C. et al. Subclinical giant cell arteritis in polymyalgia rheumatica: concurrent conditions or a common spectrum of inflammatory diseases? Autoimmun. Rev. 23, 103415 (2024).","journal-title":"Autoimmun. Rev."},{"key":"1379_CR6","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.rdc.2019.07.005","volume":"45","author":"D Camellino","year":"2019","unstructured":"Camellino, D., Dejaco, C., Buttgereit, F. & Matteson, E. L. Treat to target: a valid concept for management of polymyalgia rheumatica and giant cell arteritis? Rheum. Dis. Clin. North Am. 45, 549\u2013567 (2019).","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"1379_CR7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/ard-2022-223429","volume":"83","author":"C Dejaco","year":"2024","unstructured":"Dejaco, C. et al. Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica. Ann. Rheum. Dis. 83, 48\u201357 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1379_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000570","volume":"3","author":"S Prieto-Gonz\u00e1lez","year":"2017","unstructured":"Prieto-Gonz\u00e1lez, S. et al. Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients. RMD Open\u00a03, e000570 (2017).","journal-title":"RMD Open"},{"key":"1379_CR9","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1093\/rheumatology\/kez034","volume":"58","author":"Y van Sleen","year":"2019","unstructured":"van Sleen, Y. et al. Markers of angiogenesis and macrophage products for predicting disease course and monitoring vascular inflammation in giant cell arteritis. Rheumatology 58, 1383\u20131392 (2019).","journal-title":"Rheumatology"},{"key":"1379_CR10","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1136\/ard.2010.133850","volume":"70","author":"C Dejaco","year":"2011","unstructured":"Dejaco, C. et al. Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus. Ann. Rheum. Dis. 70, 447\u2013453 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"1379_CR11","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/rheumatology\/keae428","volume":"64","author":"TE Bolhuis","year":"2025","unstructured":"Bolhuis, T. E. et al. Definitions of and instruments for disease activity, remission and relapse in polymyalgia rheumatica: a systematic literature review. Rheumatology 64, 455\u2013469 (2025).","journal-title":"Rheumatology"},{"key":"1379_CR12","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/ard-2022-223751","volume":"82","author":"C Dejaco","year":"2023","unstructured":"Dejaco, C. et al. What is a response in randomised controlled trials in giant cell arteritis? Ann. Rheum. Dis. 82, 897\u2013900 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"1379_CR13","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1001\/jama.1957.02970450023007","volume":"163","author":"NC Birkhead","year":"1957","unstructured":"Birkhead, N. C., Wagener, H. P. & Shick, R. M. Treatment of temporal arteritis with adrenal corticosteroids; results in fifty-five cases in which lesion was proved at biopsy. J. Am. Med. Assoc. 163, 821\u2013827 (1957).","journal-title":"J. Am. Med. Assoc."},{"key":"1379_CR14","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1002\/art.41774","volume":"73","author":"M Maz","year":"2021","unstructured":"Maz, M. et al. 2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Rheumatol. 73, 1349\u20131365 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"1379_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","volume":"79","author":"B Hellmich","year":"2020","unstructured":"Hellmich, B. et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann. Rheumatic Dis. 79, 19\u201330 (2020).","journal-title":"Ann. Rheumatic Dis."},{"key":"1379_CR16","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/rheumatology\/kev348","volume":"55","author":"C Labarca","year":"2016","unstructured":"Labarca, C. et al. Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study. Rheumatology 55, 347\u2013356 (2016).","journal-title":"Rheumatology"},{"key":"1379_CR17","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1034\/j.1600-0420.2002.800403.x","volume":"80","author":"SS Hayreh","year":"2002","unstructured":"Hayreh, S. S., Zimmerman, B. & Kardon, R. H. Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature. Acta Ophthalmol. Scand. 80, 355\u2013367 (2002).","journal-title":"Acta Ophthalmol. Scand."},{"key":"1379_CR18","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/nrrheum.2017.98","volume":"13","author":"A Soriano","year":"2017","unstructured":"Soriano, A. et al. Visual loss and other cranial ischaemic complications in giant cell arteritis. Nat. Rev. Rheumatol. 13, 476\u2013484 (2017).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1379_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2023.105641","volume":"91","author":"R For\u00e9","year":"2024","unstructured":"For\u00e9, R. et al. BOB-ACG study: pulse methylprednisolone to prevent bilateral ophthalmologic damage in giant cell arteritis. A multicentre retrospective study with propensity score analysis. Jt Bone Spine 91, 105641 (2024).","journal-title":"Jt Bone Spine"},{"key":"1379_CR20","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.1002\/art.22163","volume":"54","author":"M Mazlumzadeh","year":"2006","unstructured":"Mazlumzadeh, M. et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum. 54, 3310\u20133318 (2006).","journal-title":"Arthritis Rheum."},{"key":"1379_CR21","first-page":"1484","volume":"27","author":"P Chevalet","year":"2000","unstructured":"Chevalet, P. et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J. Rheumatol. 27, 1484\u20131491 (2000).","journal-title":"J. Rheumatol."},{"key":"1379_CR22","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1002\/art.22754","volume":"56","author":"AD Mahr","year":"2007","unstructured":"Mahr, A. D. et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 56, 2789\u20132797 (2007).","journal-title":"Arthritis Rheum."},{"key":"1379_CR23","unstructured":"Samson, M. et al. Methotrexate versus tocilizumab for treatment of giant cell arteritis (METOGiA trial): a multicenter, randomized, controlled trial. Arthritis Rheumatol. 77 (Suppl. 9), abstr. 0891 (2025)."},{"key":"1379_CR24","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1136\/ard.45.2.136","volume":"45","author":"M De Silva","year":"1986","unstructured":"De Silva, M. & Hazleman, B. L. Azathioprine in giant cell arteritis\/polymyalgia rheumatica: a double-blind study. Ann. Rheum. Dis. 45, 136\u2013138 (1986).","journal-title":"Ann. Rheum. Dis."},{"key":"1379_CR25","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1080\/03009740500474537","volume":"35","author":"C Schaufelberger","year":"2006","unstructured":"Schaufelberger, C., M\u00f6llby, H., Uddhammar, A., Bratt, J. & Nordborg, E. No additional steroid-sparing effect of cyclosporine A in giant cell arteritis. Scand. J. Rheumatol. 35, 327\u2013329 (2006).","journal-title":"Scand. J. Rheumatol."},{"key":"1379_CR26","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/art.1780260521","volume":"26","author":"P Doury","year":"1983","unstructured":"Doury, P., Pattin, S., Eulry, F. & Thabaut, A. The use of dapsone in the treatment of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 26, 689\u2013690 (1983).","journal-title":"Arthritis Rheum."},{"key":"1379_CR27","first-page":"485","volume":"61","author":"P Le Guennec","year":"1994","unstructured":"Le Guennec, P. et al. [Treatment of Horton disease. Value of synthetic antimalarials. Apropos of a retrospective study of 36 patients]. Rev. Rhum. Ed. Fr. 61, 485\u2013490 (1994).","journal-title":"Rev. Rhum. Ed. Fr."},{"key":"1379_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1069013","volume":"9","author":"J Kramari\u010d","year":"2022","unstructured":"Kramari\u010d, J., Rotar, \u017d, Tom\u0161i\u010d, M. & Ho\u010devar, A. Performance of leflunomide as a steroid-sparing agent in giant cell arteritis: a single-center, open-label study. Front. Med. 9, 1069013 (2022).","journal-title":"Front. Med."},{"key":"1379_CR29","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1093\/rheumatology\/kes127","volume":"51","author":"L Quartuccio","year":"2012","unstructured":"Quartuccio, L. et al. Role of oral cyclophosphamide in the treatment of giant cell arteritis. Rheumatology 51, 1677\u20131686 (2012).","journal-title":"Rheumatology"},{"key":"1379_CR30","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/rheumatology\/ken465","volume":"48","author":"C Salvarani","year":"2009","unstructured":"Salvarani, C. et al. Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. Rheumatology 48, 250\u2013253 (2009).","journal-title":"Rheumatology"},{"key":"1379_CR31","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/rheumatology\/ken480","volume":"48","author":"CT Berger","year":"2009","unstructured":"Berger, C. T., Wolbers, M., Meyer, P., Daikeler, T. & Hess, C. High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition. Rheumatology 48, 258\u2013261 (2009).","journal-title":"Rheumatology"},{"key":"1379_CR32","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1002\/art.20171","volume":"50","author":"G Nesher","year":"2004","unstructured":"Nesher, G. et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum. 50, 1332\u20131337 (2004).","journal-title":"Arthritis Rheum."},{"key":"1379_CR33","volume":"2014","author":"SP Mollan","year":"2014","unstructured":"Mollan, S. P., Sharrack, N., Burdon, M. A. & Denniston, A. K. Aspirin as adjunctive treatment for giant cell arteritis. Cochrane Database Syst. Rev. 2014, CD010453 (2014).","journal-title":"Cochrane Database Syst. Rev."},{"key":"1379_CR34","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1136\/ard-2024-225515","volume":"84","author":"NJM Chaddock","year":"2025","unstructured":"Chaddock, N. J. M. et al. Age, anticoagulants, hypertension and cardiovascular genetic traits predict cranial ischaemic complications in patients with giant cell arteritis. Ann. Rheum. Dis. 84, 329\u2013340 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"1379_CR35","doi-asserted-by":"publisher","first-page":"e874","DOI":"10.1016\/S2665-9913(21)00253-8","volume":"3","author":"F Ciccia","year":"2021","unstructured":"Ciccia, F. et al. New insights into the pathogenesis of giant cell arteritis: are they relevant for precision medicine? Lancet Rheumatol. 3, e874\u2013e885 (2021).","journal-title":"Lancet Rheumatol."},{"key":"1379_CR36","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1161\/CIRCRESAHA.122.322128","volume":"132","author":"CM Weyand","year":"2023","unstructured":"Weyand, C. M. & Goronzy, J. J. Immunology of giant cell arteritis. Circ. Res. 132, 238\u2013250 (2023).","journal-title":"Circ. Res."},{"key":"1379_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103186","volume":"144","author":"M Bonacini","year":"2024","unstructured":"Bonacini, M. et al. miR-146a and miR-146b regulate the expression of ICAM-1 in giant cell arteritis. J. Autoimmun. 144, 103186 (2024).","journal-title":"J. Autoimmun."},{"key":"1379_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14186350","volume":"14","author":"M Shiomi","year":"2025","unstructured":"Shiomi, M. et al. Uncovering the new biology of giant cell arteritis to guide therapeutic strategies. J. Clin. Med. 14, 6350 (2025).","journal-title":"J. Clin. Med."},{"key":"1379_CR39","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1084\/jem.20030850","volume":"199","author":"W Ma-Krupa","year":"2004","unstructured":"Ma-Krupa, W. et al. Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J. Exp. Med. 199, 173\u2013183 (2004).","journal-title":"J. Exp. Med."},{"key":"1379_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101012","volume":"4","author":"S Ohtsuki","year":"2023","unstructured":"Ohtsuki, S. et al. Deficiency of the CD155-CD96 immune checkpoint controls IL-9 production in giant cell arteritis. Cell Rep. Med. 4, 101012 (2023).","journal-title":"Cell Rep. Med."},{"key":"1379_CR41","first-page":"E970","volume":"114","author":"H Zhang","year":"2017","unstructured":"Zhang, H. et al. Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis. Proc. Natl Acad. Sci. USA 114, E970\u2013E979 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1379_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004600","volume":"10","author":"I Ferrigno","year":"2024","unstructured":"Ferrigno, I. et al. Genes deregulated in giant cell arteritis by Nanostring nCounter gene expression profiling in temporal artery biopsies. RMD Open\u00a010, e004600 (2024).","journal-title":"RMD Open"},{"key":"1379_CR43","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.jbspin.2016.07.005","volume":"84","author":"R Watanabe","year":"2017","unstructured":"Watanabe, R. et al. Pro-inflammatory and anti-inflammatory T cells in giant cell arteritis. Jt Bone Spine 84, 421\u2013426 (2017).","journal-title":"Jt Bone Spine"},{"key":"1379_CR44","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.jacc.2019.01.049","volume":"73","author":"H Zhang","year":"2019","unstructured":"Zhang, H. et al. CD28 signaling controls metabolic fitness of pathogenic T cells in medium and large vessel vasculitis. J. Am. Coll. Cardiol. 73, 1811\u20131823 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1379_CR45","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1161\/CIRCRESAHA.118.313206","volume":"123","author":"R Watanabe","year":"2018","unstructured":"Watanabe, R. et al. MMP (matrix metalloprotease)-9-producing monocytes enable T cells to invade the vessel wall and cause vasculitis. Circ. Res. 123, 700\u2013715 (2018).","journal-title":"Circ. Res."},{"key":"1379_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10214958","volume":"10","author":"I Esen","year":"2021","unstructured":"Esen, I. et al. Functionally heterogenous macrophage subsets in the pathogenesis of giant cell arteritis: novel targets for disease monitoring and treatment. J. Clin. Med. 10, 4958 (2021).","journal-title":"J. Clin. Med."},{"key":"1379_CR47","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1097\/PAS.0000000000000244","volume":"38","author":"A Cavazza","year":"2014","unstructured":"Cavazza, A. et al. Inflamed temporal artery: histologic findings in 354 biopsies, with clinical correlations. Am. J. Surg. Pathol. 38, 1360\u20131370 (2014).","journal-title":"Am. J. Surg. Pathol."},{"key":"1379_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1197293","volume":"14","author":"M van Nieuwland","year":"2023","unstructured":"van Nieuwland, M. et al. Evidence for increased interferon type I activity in CD8+ T cells in giant cell arteritis patients. Front. Immunol. 14, 1197293 (2023).","journal-title":"Front. Immunol."},{"key":"1379_CR49","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1093\/rheumatology\/keab505","volume":"61","author":"DA Palamidas","year":"2022","unstructured":"Palamidas, D. A. et al. Neutrophil extracellular traps in giant cell arteritis biopsies: presentation, localization and co-expression with inflammatory cytokines. Rheumatology 61, 1639\u20131644 (2022).","journal-title":"Rheumatology"},{"key":"1379_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2023.103111","volume":"140","author":"JC Graver","year":"2023","unstructured":"Graver, J. C. et al. Cytokine producing B-cells and their capability to polarize macrophages in giant cell arteritis. J. Autoimmun. 140, 103111 (2023).","journal-title":"J. Autoimmun."},{"key":"1379_CR51","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1136\/annrheumdis-2016-209217","volume":"76","author":"F Ciccia","year":"2017","unstructured":"Ciccia, F. et al. Ectopic expression of CXCL13, BAFF, APRIL and LT-\u03b2 is associated with artery tertiary lymphoid organs in giant cell arteritis. Ann. Rheum. Dis. 76, 235\u2013243 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"1379_CR52","first-page":"1317","volume":"42","author":"E Pesce","year":"2024","unstructured":"Pesce, E. et al. Identification of two autoantigens recognised by circulating autoantibodies as potential biomarkers for diagnosing giant cell arteritis. Clin. Exp. Rheumatol. 42, 1317\u20131320 (2024).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1379_CR53","doi-asserted-by":"publisher","first-page":"4382","DOI":"10.1093\/rheumatology\/keaf143","volume":"64","author":"S Xu","year":"2025","unstructured":"Xu, S. et al. Distinct landscapes of fibroblast subtypes in arteries of patients with giant cell arteritis. Rheumatology 64, 4382\u20134392 (2025).","journal-title":"Rheumatology"},{"key":"1379_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103574","volume":"23","author":"S Xu","year":"2024","unstructured":"Xu, S. et al. Current evidence on the role of fibroblasts in large-vessel vasculitides: from pathogenesis to therapeutics. Autoimmun. Rev. 23, 103574 (2024).","journal-title":"Autoimmun. Rev."},{"key":"1379_CR55","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1136\/ard-2023-224467","volume":"83","author":"D Veroutis","year":"2024","unstructured":"Veroutis, D. et al. Senescent cells in giant cell arteritis display an inflammatory phenotype participating in tissue injury via IL-6-dependent pathways. Ann. Rheum. Dis. 83, 342\u2013350 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1379_CR56","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1161\/CIRCULATIONAHA.117.030423","volume":"137","author":"H Zhang","year":"2018","unstructured":"Zhang, H. et al. Inhibition of JAK-STAT signaling suppresses pathogenic immune responses in medium and large vessel vasculitis. Circulation 137, 1934\u20131948 (2018).","journal-title":"Circulation"},{"key":"1379_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1199059","volume":"14","author":"M Zeisbrich","year":"2023","unstructured":"Zeisbrich, M., Thiel, J. & Venhoff, N. The IL-17 pathway as a target in giant cell arteritis. Front. Immunol. 14, 1199059 (2023).","journal-title":"Front. Immunol."},{"key":"1379_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00809","volume":"9","author":"G Esp\u00edgol-Frigol\u00e9","year":"2018","unstructured":"Esp\u00edgol-Frigol\u00e9, G. et al. Expression and function of IL12\/23 related cytokine subunits (p35, p40, and p19) in giant-cell arteritis lesions: contribution of p40 to Th1- and Th17-mediated inflammatory pathways. Front. Immunol. 9, 809 (2018).","journal-title":"Front. Immunol."},{"key":"1379_CR59","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1136\/annrheumdis-2021-220873","volume":"81","author":"M Corbera-Bellalta","year":"2022","unstructured":"Corbera-Bellalta, M. et al. Blocking GM-CSF receptor \u03b1 with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis. Ann. Rheum. Dis. 81, 524\u2013536 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1379_CR60","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/j.ard.2025.02.008","volume":"84","author":"M Corbera-Bellalta","year":"2025","unstructured":"Corbera-Bellalta, M. et al. The IL-6 axis in vascular inflammation: effects of IL-6 receptor blockade on vascular lesions from patients with giant-cell arteritis. Ann. Rheum. Dis. 84, 1387\u20131400 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"1379_CR61","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","volume":"387","author":"PM Villiger","year":"2016","unstructured":"Villiger, P. M. et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 387, 1921\u20131927 (2016).","journal-title":"Lancet"},{"key":"1379_CR62","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","volume":"377","author":"JH Stone","year":"2017","unstructured":"Stone, J. H. et al. Trial of tocilizumab in giant-cell arteritis. N. Engl. J. Med. 377, 317\u2013328 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1379_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1837-7","volume":"21","author":"V Strand","year":"2019","unstructured":"Strand, V. et al. Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial. Arthritis Res. Ther. 21, 64 (2019).","journal-title":"Arthritis Res. Ther."},{"key":"1379_CR64","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1136\/annrheumdis-2016-209773","volume":"76","author":"A Strangfeld","year":"2017","unstructured":"Strangfeld, A. et al. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs. Ann. Rheum. Dis. 76, 504\u2013510 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"1379_CR65","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1093\/rheumatology\/kez091","volume":"58","author":"S Adler","year":"2019","unstructured":"Adler, S. et al. Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis. Rheumatology 58, 1639\u20131643 (2019).","journal-title":"Rheumatology"},{"key":"1379_CR66","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S2665-9913(21)00038-2","volume":"3","author":"JH Stone","year":"2021","unstructured":"Stone, J. H. et al. Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial. Lancet Rheumatol. 3, e328\u2013e336 (2021).","journal-title":"Lancet Rheumatol."},{"key":"1379_CR67","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1093\/rheumatology\/kead604","volume":"63","author":"V Quick","year":"2024","unstructured":"Quick, V. et al. Relapse after cessation of weekly tocilizumab for giant cell arteritis: a multicentre service evaluation in England. Rheumatology 63, 3407\u20133414 (2024).","journal-title":"Rheumatology"},{"key":"1379_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103580","volume":"23","author":"MA Alba","year":"2024","unstructured":"Alba, M. A. et al. Relapses in giant cell arteritis: updated review for clinical practice. Autoimmun. Rev. 23, 103580 (2024).","journal-title":"Autoimmun. Rev."},{"key":"1379_CR69","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.semarthrit.2021.03.006","volume":"51","author":"R Spiera","year":"2021","unstructured":"Spiera, R. et al. Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial. Semin. Arthritis Rheum. 51, 469\u2013476 (2021).","journal-title":"Semin. Arthritis Rheum."},{"key":"1379_CR70","first-page":"112","volume":"38","author":"M Calder\u00f3n-Goercke","year":"2020","unstructured":"Calder\u00f3n-Goercke, M. et al. Tocilizumab in giant cell arteritis: differences between the GiACTA trial and a multicentre series of patients from the clinical practice. Clin. Exp. Rheumatol. 38, 112\u2013119 (2020).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1379_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152508","volume":"68","author":"MK Nielsen","year":"2024","unstructured":"Nielsen, M. K. et al. Taper versus discontinuation of tocilizumab in patients with giant cell arteritis: real-world experience from a tertiary center. Semin. Arthritis Rheum. 68, 152508 (2024).","journal-title":"Semin. Arthritis Rheum."},{"key":"1379_CR72","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf450","volume":"65","author":"V Quick","year":"2026","unstructured":"Quick, V. et al. Coming to a hard stop? Effect of tapered tocilizumab after weekly tocilizumab cessation for GCA: a multicentre evaluation. Rheumatology 65, keaf450 (2026).","journal-title":"Rheumatology"},{"key":"1379_CR73","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-005132","volume":"10","author":"C Ricordi","year":"2024","unstructured":"Ricordi, C. et al. Does tocilizumab eliminate inflammation in GCA? A cohort study on repeated temporal artery biopsies. RMD Open\u00a010, e005132 (2024).","journal-title":"RMD Open"},{"key":"1379_CR74","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1093\/rheumatology\/key015","volume":"57","author":"S Reichenbach","year":"2018","unstructured":"Reichenbach, S. et al. Magnetic resonance angiography in giant cell arteritis: results of a randomized controlled trial of tocilizumab in giant cell arteritis. Rheumatology 57, 982\u2013986 (2018).","journal-title":"Rheumatology"},{"key":"1379_CR75","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1093\/rheumatology\/keab332","volume":"60","author":"V Sch\u00f6nau","year":"2021","unstructured":"Sch\u00f6nau, V. et al. Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study. Rheumatology 60, 3851\u20133861 (2021).","journal-title":"Rheumatology"},{"issue":"Suppl 129","key":"1379_CR76","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.55563\/clinexprheumatol\/mjm8fr","volume":"39","author":"D Prieto-Pe\u00f1a","year":"2021","unstructured":"Prieto-Pe\u00f1a, D. et al. Evidence for uncoupling of clinical and 18-FDG activity of PET\/CT scan improvement in tocilizumab-treated patients with large-vessel giant cell arteritis. Clin. Exp. Rheumatol. 39\u00a0(Suppl. 129), S69\u2013S75 (2021).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1379_CR77","doi-asserted-by":"publisher","first-page":"4384","DOI":"10.1093\/rheumatology\/keaa894","volume":"60","author":"KA Quinn","year":"2021","unstructured":"Quinn, K. A., Dashora, H., Novakovich, E., Ahlman, M. A. & Grayson, P. C. Use of 18F-fluorodeoxyglucose positron emission tomography to monitor tocilizumab effect on vascular inflammation in giant cell arteritis. Rheumatology 60, 4384\u20134389 (2021).","journal-title":"Rheumatology"},{"key":"1379_CR78","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/art.42405","volume":"75","author":"NJ Patel","year":"2023","unstructured":"Patel, N. J., Tozzo, V., Higgins, J. M. & Stone, J. H. The effects of daily prednisone and tocilizumab on hemoglobin A1c during the treatment of giant cell arteritis. Arthritis Rheumatol. 75, 586\u2013594 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"1379_CR79","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s40744-020-00227-2","volume":"7","author":"WA Schmidt","year":"2020","unstructured":"Schmidt, W. A. et al. A multicentre, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of sirukumab in the treatment of giant cell arteritis. Rheumatol. Ther. 7, 793\u2013810 (2020).","journal-title":"Rheumatol. Ther."},{"key":"1379_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-023-03177-6","volume":"25","author":"WA Schmidt","year":"2023","unstructured":"Schmidt, W. A. et al. A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis. Arthritis Res. Ther. 25, 199 (2023).","journal-title":"Arthritis Res. Ther."},{"key":"1379_CR81","doi-asserted-by":"publisher","first-page":"e736","DOI":"10.1016\/S2665-9913(23)00265-5","volume":"5","author":"S Unizony","year":"2023","unstructured":"Unizony, S. et al. Treatment for giant cell arteritis with 8 weeks of prednisone in combination with tocilizumab: a single-arm, open-label, proof-of-concept study. Lancet. Rheumatol. 5, e736\u2013e742 (2023).","journal-title":"Lancet. Rheumatol."},{"key":"1379_CR82","doi-asserted-by":"publisher","first-page":"e619","DOI":"10.1016\/S2665-9913(21)00152-1","volume":"3","author":"L Christ","year":"2021","unstructured":"Christ, L. et al. Tocilizumab monotherapy after ultra-short glucocorticoid administration in giant cell arteritis: a single-arm, open-label, proof-of-concept study. Lancet Rheumatol. 3, e619\u2013e626 (2021).","journal-title":"Lancet Rheumatol."},{"key":"1379_CR83","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/rheumatology\/kead215","volume":"63","author":"F Muratore","year":"2024","unstructured":"Muratore, F. et al. Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: the role of imaging in a prospective observational study. Rheumatology 63, 64\u201371 (2024).","journal-title":"Rheumatology"},{"key":"1379_CR84","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1056\/NEJMoa2413449","volume":"392","author":"D Blockmans","year":"2025","unstructured":"Blockmans, D. et al. A phase 3 trial of upadacitinib for giant-cell arteritis. N. Engl. J. Med. 392, 2013\u20132024 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1379_CR85","doi-asserted-by":"crossref","unstructured":"Schmidt, W. et al. Efficacy and safety of upadacitinib in giant cell arteritis: 2-year results from the re-randomized, double-blind SELECT-GCA phase 3 trial. Arthritis Rheumatol. 77 (Suppl. 9), abstr. 0776 (2025).","DOI":"10.1093\/rheumatology\/keag121.017"},{"key":"1379_CR86","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1136\/annrheumdis-2021-221961","volume":"81","author":"MJ Koster","year":"2022","unstructured":"Koster, M. J. et al. Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study. Ann. Rheum. Dis. 81, 861\u2013867 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1379_CR87","doi-asserted-by":"publisher","first-page":"621","DOI":"10.7326\/0003-4819-146-9-200705010-00004","volume":"146","author":"GS Hoffman","year":"2007","unstructured":"Hoffman, G. S. et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann. Intern. Med. 146, 621\u2013630 (2007).","journal-title":"Ann. Intern. Med."},{"key":"1379_CR88","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1136\/annrheumdis-2013-203586","volume":"73","author":"R Seror","year":"2013","unstructured":"Seror, R. et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. Ann. Rheum. Dis. 73, 2074\u20132081 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"1379_CR89","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1136\/ard.2007.082115","volume":"67","author":"VM Mart\u00ednez-Taboada","year":"2008","unstructured":"Mart\u00ednez-Taboada, V. M. et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann. Rheum. Dis. 67, 625\u2013630 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"1379_CR90","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1016\/S2665-9913(23)00101-7","volume":"5","author":"N Venhoff","year":"2023","unstructured":"Venhoff, N. et al. Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Rheumatol. 5, e341\u2013e350 (2023).","journal-title":"Lancet Rheumatol."},{"key":"1379_CR91","doi-asserted-by":"crossref","unstructured":"Novartis provides update on Phase III GCAptAIN study of Cosentyx\u00ae in giant cell arteritis (GCA). Novartis https:\/\/www.novartis.com\/news\/media-releases\/novartis-provides-update-phase-iii-gcaptain-study-cosentyx-giant-cell-arteritis-gca (2025).","DOI":"10.69645\/DQFX6833"},{"key":"1379_CR92","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/acr.24200","volume":"73","author":"MA Matza","year":"2021","unstructured":"Matza, M. A., Fernandes, A. D., Stone, J. H. & Unizony, S. H. Ustekinumab for the treatment of giant cell arteritis. Arthritis Care Res. 73, 893\u2013897 (2021).","journal-title":"Arthritis Care Res."},{"key":"1379_CR93","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-025-03493-z","volume":"27","author":"H de Boysson","year":"2025","unstructured":"de Boysson, H. et al. Four months of treatment with anakinra combined with glucocorticoids for giant cell arteritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Res. Ther. 27, 122 (2025).","journal-title":"Arthritis Res. Ther."},{"key":"1379_CR94","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.ard.2026.01.009","volume":"85","author":"J-P Makhzoum","year":"2026","unstructured":"Makhzoum, J.-P. et al. A phase 2, randomised, placebo-controlled study of guselkumab in adults with new-onset or relapsing giant cell arteritis. Ann. Rheum. Dis. 85, 911\u2013920\u00a0(2026).","journal-title":"Ann. Rheum. Dis."},{"key":"1379_CR95","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1136\/annrheumdis-2021-221865","volume":"81","author":"MC Cid","year":"2022","unstructured":"Cid, M. C. et al. Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 81, 653\u2013661 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1379_CR96","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/art.40044","volume":"69","author":"CA Langford","year":"2017","unstructured":"Langford, C. A. et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol. 69, 837\u2013845 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"1379_CR97","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1093\/rheumatology\/kez664","volume":"59","author":"SL Mackie","year":"2020","unstructured":"Mackie, S. L. et al. British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. Rheumatology 59, 487\u2013494 (2020).","journal-title":"Rheumatology"},{"key":"1379_CR98","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00393-020-00893-1","volume":"79","author":"JH Schirmer","year":"2020","unstructured":"Schirmer, J. H. et al. [S2k guidelines: management of large-vessel vasculitis]. Z. Rheumatol. 79, 67\u201395 (2020).","journal-title":"Z. Rheumatol."},{"key":"1379_CR99","doi-asserted-by":"publisher","unstructured":"Ughi, N. et al. The Italian Society of Rheumatology clinical practice guidelines for the management of large vessel vasculitis. Reumatismo https:\/\/doi.org\/10.4081\/reumatismo.2021.1470 (2022).","DOI":"10.4081\/reumatismo.2021.1470"},{"key":"1379_CR100","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/03009742.2019.1571223","volume":"48","author":"C Turesson","year":"2019","unstructured":"Turesson, C., B\u00f6rjesson, O., Larsson, K., Mohammad, A. J. & Knight, A. Swedish Society of Rheumatology 2018 guidelines for investigation, treatment, and follow-up of giant cell arteritis. Scand. J. Rheumatol. 48, 259\u2013265 (2019).","journal-title":"Scand. J. Rheumatol."},{"key":"1379_CR101","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.revmed.2024.10.006","volume":"46","author":"H de Boysson","year":"2025","unstructured":"de Boysson, H. et al. Use of immunosuppressants and biologics in giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA). Rev. Med. Interne 46, 4\u201311 (2025).","journal-title":"Rev. Med. Interne"},{"key":"1379_CR102","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41584-021-00686-z","volume":"17","author":"B Hellmich","year":"2021","unstructured":"Hellmich, B. & Buttgereit, F. GCA management guidelines \u2014 vive la diff\u00e9rence? Nat. Rev. Rheumatol. 17, 649\u2013650 (2021).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1379_CR103","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001003","volume":"5","author":"S Monti","year":"2019","unstructured":"Monti, S. et al. Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis. RMD Open\u00a05, e001003 (2019).","journal-title":"RMD Open"},{"key":"1379_CR104","doi-asserted-by":"publisher","first-page":"e864","DOI":"10.1016\/S2665-9913(22)00260-0","volume":"4","author":"M Scolnik","year":"2022","unstructured":"Scolnik, M. et al. Pan American League of Associations for Rheumatology guidelines for the treatment of giant cell arteritis. Lancet Rheumatol. 4, e864\u2013e872 (2022).","journal-title":"Lancet Rheumatol."},{"key":"1379_CR105","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3899\/jrheum.2022-1214","volume":"50","author":"MJ Samec","year":"2023","unstructured":"Samec, M. J. et al. Relapse risk and safety of long-term tocilizumab use among patients with giant cell arteritis: a single-enterprise cohort study. J. Rheumatol. 50, 1310\u20131317 (2023).","journal-title":"J. Rheumatol."},{"key":"1379_CR106","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/art.43098","volume":"77","author":"MA Alba","year":"2025","unstructured":"Alba, M. A. et al. Management of relapses in giant cell arteritis. Arthritis Rheumatol. 77, 632\u2013645 (2025).","journal-title":"Arthritis Rheumatol."},{"key":"1379_CR107","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1136\/ard-2023-224543","volume":"83","author":"C Dejaco","year":"2023","unstructured":"Dejaco, C. et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update. Ann. Rheum. Dis. 83, 741\u2013751 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"1379_CR108","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.7326\/M23-0679","volume":"176","author":"L Moreel","year":"2023","unstructured":"Moreel, L. et al. Association between vascular 18F-fluorodeoxyglucose uptake at diagnosis and change in aortic dimensions in giant cell arteritis: a cohort study. Ann. Intern. Med. 176, 1321\u20131329 (2023).","journal-title":"Ann. Intern. Med."},{"key":"1379_CR109","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003775","volume":"10","author":"MM Elfishawi","year":"2024","unstructured":"Elfishawi, M. M. et al. Reappraisal of large artery involvement in giant cell arteritis: a population-based cohort over 70 years. RMD Open\u00a010, e003775 (2024).","journal-title":"RMD Open"},{"key":"1379_CR110","doi-asserted-by":"publisher","first-page":"502","DOI":"10.7326\/0003-4819-122-7-199504010-00004","volume":"122","author":"JM Evans","year":"1995","unstructured":"Evans, J. M., O\u2019Fallon, W. M. & Hunder, G. G. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann. Intern. Med. 122, 502\u2013507 (1995).","journal-title":"Ann. Intern. Med."},{"key":"1379_CR111","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.amjcard.2017.11.011","volume":"121","author":"DT Kebed","year":"2018","unstructured":"Kebed, D. T. et al. Spectrum of aortic disease in the giant cell arteritis population. Am. J. Cardiol. 121, 501\u2013508 (2018).","journal-title":"Am. J. Cardiol."},{"key":"1379_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2023.101827","volume":"37","author":"CE Owen","year":"2023","unstructured":"Owen, C. E. et al. Imaging of giant cell arteritis \u2014 recent advances. Best. Pract. Res. Clin. Rheumatol. 37, 101827 (2023).","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"1379_CR113","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/acr.20435","volume":"63","author":"TA Kermani","year":"2011","unstructured":"Kermani, T. A., Ytterberg, S. R. & Warrington, K. J. Pneumocystis jiroveci pneumonia in giant cell arteritis: a case series. Arthritis Care Res. 63, 761\u2013765 (2011).","journal-title":"Arthritis Care Res."},{"key":"1379_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152154","volume":"58","author":"N Anumolu","year":"2023","unstructured":"Anumolu, N., Henry, K., Sattui, S. E. & Putman, M. Is there a role for Pneumocystis jiroveci pneumonia prophylaxis in giant cell arteritis or polymyalgia rheumatica? Semin. Arthritis Rheum. 58, 152154 (2023).","journal-title":"Semin. Arthritis Rheum."},{"key":"1379_CR115","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jiac.2019.01.005","volume":"25","author":"T Kitazawa","year":"2019","unstructured":"Kitazawa, T. et al. Efficacies of atovaquone, pentamidine, and trimethoprim\/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases. J. Infect. Chemother. 25, 351\u2013354 (2019).","journal-title":"J. Infect. Chemother."},{"key":"1379_CR116","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1002\/art.42646","volume":"75","author":"MB Humphrey","year":"2023","unstructured":"Humphrey, M. B. et al. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol. 75, 2088\u20132102 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"1379_CR117","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s10067-021-05819-z","volume":"41","author":"A Floris","year":"2022","unstructured":"Floris, A. et al. Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis. Clin. Rheumatol. 41, 19\u201331 (2022).","journal-title":"Clin. Rheumatol."},{"key":"1379_CR118","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkac034","volume":"6","author":"S Muller","year":"2022","unstructured":"Muller, S. et al. Long-term use of glucocorticoids for polymyalgia rheumatica: follow-up of the PMR Cohort Study. Rheumatol. Adv. Pract. 6, rkac034 (2022).","journal-title":"Rheumatol. Adv. Pract."},{"key":"1379_CR119","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1136\/annrheumdis-2015-207492","volume":"74","author":"C Dejaco","year":"2015","unstructured":"Dejaco, C. et al. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative. Ann. Rheum. Dis. 74, 1799\u20131807 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"1379_CR120","doi-asserted-by":"publisher","first-page":"E680","DOI":"10.1503\/cmaj.190178","volume":"191","author":"J Wu","year":"2019","unstructured":"Wu, J., Keeley, A., Mallen, C., Morgan, A. W. & Pujades-Rodriguez, M. Incidence of infections associated with oral glucocorticoid dose in people diagnosed with polymyalgia rheumatica or giant cell arteritis: a cohort study in England. CMAJ 191, E680\u2013E688 (2019).","journal-title":"CMAJ"},{"key":"1379_CR121","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/rheumatology\/37.2.189","volume":"37","author":"B Dasgupta","year":"1998","unstructured":"Dasgupta, B., Dolan, A. L., Panayi, G. S. & Fernandes, L. An initially double-blind controlled 96 week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica. Br. J. Rheumatol. 37, 189\u2013195 (1998).","journal-title":"Br. J. Rheumatol."},{"key":"1379_CR122","first-page":"1470","volume":"27","author":"C Salvarani","year":"2000","unstructured":"Salvarani, C. et al. Corticosteroid injections in polymyalgia rheumatica: a double-blind, prospective, randomized, placebo controlled study. J. Rheumatol. 27, 1470\u20131476 (2000).","journal-title":"J. Rheumatol."},{"key":"1379_CR123","doi-asserted-by":"publisher","first-page":"493","DOI":"10.7326\/0003-4819-141-7-200410050-00005","volume":"141","author":"R Caporali","year":"2004","unstructured":"Caporali, R. et al. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 141, 493\u2013500 (2004).","journal-title":"Ann. Intern. Med."},{"key":"1379_CR124","first-page":"624","volume":"23","author":"G Ferraccioli","year":"1996","unstructured":"Ferraccioli, G., Salaffi, F., De Vita, S., Casatta, L. & Bartoli, E. Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study. J. Rheumatol. 23, 624\u2013628 (1996).","journal-title":"J. Rheumatol."},{"key":"1379_CR125","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1136\/ard.55.4.218","volume":"55","author":"MJ van der Veen","year":"1996","unstructured":"van der Veen, M. J., Dinant, H. J., van Booma-Frankfort, C., van Albada-Kuipers, G. A. & Bijlsma, J. W. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann. Rheum. Dis. 55, 218\u2013223 (1996).","journal-title":"Ann. Rheum. Dis."},{"key":"1379_CR126","first-page":"395","volume":"26","author":"MA Cimmino","year":"2008","unstructured":"Cimmino, M. A. et al. Long-term follow-up of polymyalgia rheumatica patients treated with methotrexate and steroids. Clin. Exp. Rheumatol. 26, 395\u2013400 (2008).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1379_CR127","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.ard.2025.11.025","volume":"85","author":"TE Bolhuis","year":"2026","unstructured":"Bolhuis, T. E. et al. Results of a 1-year randomised double-blind placebo-controlled trial with methotrexate 25 mg\/week in recently diagnosed polymyalgia rheumatica. Ann. Rheum. Dis. 85, 761\u2013770 (2026).","journal-title":"Ann. Rheum. Dis."},{"key":"1379_CR128","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkae033","volume":"8","author":"JP Vinicki","year":"2024","unstructured":"Vinicki, J. P. et al. Effectiveness of methotrexate and leflunomide as corticoid-sparing drugs in patients with polymyalgia rheumatica. Rheumatol. Adv. Pract. 8, rkae033 (2024).","journal-title":"Rheumatol. Adv. Pract."},{"key":"1379_CR129","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2023.12242","volume":"26","author":"MM Florescu","year":"2023","unstructured":"Florescu, M. M. et al. Polymyalgia rheumatica: an update (Review). Exp. Ther. Med. 26, 543 (2023).","journal-title":"Exp. Ther. Med."},{"key":"1379_CR130","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s10067-023-06708-3","volume":"43","author":"I Coskun Benlidayi","year":"2024","unstructured":"Coskun Benlidayi, I. Why is polymyalgia rheumatica a disease of older adults? Explanations through etiology and pathogenesis: a narrative review. Clin. Rheumatol. 43, 851\u2013861 (2024).","journal-title":"Clin. Rheumatol."},{"key":"1379_CR131","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1093\/rheumatology\/keu526","volume":"54","author":"KSM van der Geest","year":"2015","unstructured":"van der Geest, K. S. M. et al. Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica. Rheumatology 54, 1397\u20131402 (2015).","journal-title":"Rheumatology"},{"key":"1379_CR132","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102995","volume":"21","author":"E Hysa","year":"2022","unstructured":"Hysa, E. et al. Immune system activation in polymyalgia rheumatica: which balance between autoinflammation and autoimmunity? A systematic review. Autoimmun. Rev. 21, 102995 (2022).","journal-title":"Autoimmun. Rev."},{"key":"1379_CR133","doi-asserted-by":"publisher","first-page":"e758","DOI":"10.1016\/S2665-9913(21)00245-9","volume":"3","author":"DE Marsman","year":"2021","unstructured":"Marsman, D. E., Broeder, N., den Hoogen, F. H. J., van den Broeder, A. A. & van den Maas, A. Efficacy of rituximab in patients with polymyalgia rheumatica: a double-blind, randomised, placebo-controlled, proof-of-concept trial. Lancet Rheumatol. 3, e758\u2013e766 (2021).","journal-title":"Lancet Rheumatol."},{"key":"1379_CR134","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.943574","volume":"13","author":"RD Reitsema","year":"2022","unstructured":"Reitsema, R. D. et al. Contribution of pathogenic T helper 1 and 17 cells to bursitis and tenosynovitis in polymyalgia rheumatica. Front. Immunol. 13, 943574 (2022).","journal-title":"Front. Immunol."},{"key":"1379_CR135","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.ard.2025.01.004","volume":"84","author":"WF Jiemy","year":"2025","unstructured":"Jiemy, W. F. et al. GM-CSF drives IL-6 production by macrophages in polymyalgia rheumatica. Ann. Rheum. Dis. 84, 833\u2013843 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"1379_CR136","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0140-6736(23)01310-7","volume":"402","author":"G Esp\u00edgol-Frigol\u00e9","year":"2023","unstructured":"Esp\u00edgol-Frigol\u00e9, G. et al. Polymyalgia rheumatica. Lancet 402, 1459\u20131472 (2023).","journal-title":"Lancet"},{"key":"1379_CR137","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/joim.13525","volume":"292","author":"IE Lundberg","year":"2022","unstructured":"Lundberg, I. E., Sharma, A., Turesson, C. & Mohammad, A. J. An update on polymyalgia rheumatica. J. Intern. Med. 292, 717\u2013732 (2022).","journal-title":"J. Intern. Med."},{"key":"1379_CR138","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1002\/art.1780390719","volume":"39","author":"R Meliconi","year":"1996","unstructured":"Meliconi, R. et al. Leukocyte infiltration in synovial tissue from the shoulder of patients with polymyalgia rheumatica. Quantitative analysis and influence of corticosteroid treatment. Arthritis Rheum. 39, 1199\u20131207 (1996).","journal-title":"Arthritis Rheum."},{"key":"1379_CR139","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2024.105730","volume":"91","author":"D Wendling","year":"2024","unstructured":"Wendling, D. et al. Recommendations of the French Society of Rheumatology for the management in current practice of patients with polymyalgia rheumatica. Jt Bone Spine 91, 105730 (2024).","journal-title":"Jt Bone Spine"},{"key":"1379_CR140","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s00393-025-01667-3","volume":"84","author":"F Buttgereit","year":"2025","unstructured":"Buttgereit, F. et al. [S2e guidelines on the treatment of polymyalgia rheumatica: update 2024: evidence-based guidelines of the German Society for Rheumatology and Clinical Immunology (DGRh), the Austrian Society for Rheumatology and Rehabilitation (\u00d6GR) and the Swiss Society for Rheumatology (SGR) and the participating medical scientific specialist societies and other organizations]. Z. Rheumatol. 84, 494\u2013505 (2025).","journal-title":"Z. Rheumatol."},{"key":"1379_CR141","doi-asserted-by":"publisher","first-page":"6036","DOI":"10.1093\/rheumatology\/keaf418","volume":"64","author":"Z Boyadzhieva","year":"2025","unstructured":"Boyadzhieva, Z., Reisch, M., Schneider, M., Buttgereit, F. & Dejaco, C. Treatment and prognostic factors in polymyalgia rheumatica: a systematic literature review informing German, Austrian and Swiss guidelines. Rheumatology 64, 6036\u20136047 (2025).","journal-title":"Rheumatology"},{"key":"1379_CR142","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10132948","volume":"10","author":"K Izumi","year":"2021","unstructured":"Izumi, K. et al. Steroid-sparing effect of tocilizumab and methotrexate in patients with polymyalgia rheumatica: a retrospective cohort study. J. Clin. Med. 10, 2948 (2021).","journal-title":"J. Clin. Med."},{"key":"1379_CR143","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1093\/rheumatology\/kead426","volume":"63","author":"M Assaraf","year":"2024","unstructured":"Assaraf, M. et al. Efficacy and management of tocilizumab in polymyalgia rheumatica: results of a multicentre retrospective observational study. Rheumatology 63, 2065\u20132073 (2024).","journal-title":"Rheumatology"},{"key":"1379_CR144","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1136\/annrheumdis-2015-208742","volume":"75","author":"V Devauchelle-Pensec","year":"2016","unstructured":"Devauchelle-Pensec, V. et al. Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study. Ann. Rheum. Dis. 75, 1506\u20131510 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"1379_CR145","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1002\/art.39740","volume":"68","author":"L Lally","year":"2016","unstructured":"Lally, L., Forbess, L., Hatzis, C. & Spiera, R. Brief report: a prospective open-label phase IIa trial of tocilizumab in the treatment of polymyalgia rheumatica. Arthritis Rheumatol. 68, 2550\u20132554 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"1379_CR146","doi-asserted-by":"publisher","first-page":"795","DOI":"10.3899\/jrheum.110977","volume":"39","author":"EL Matteson","year":"2012","unstructured":"Matteson, E. L. et al. Patient-reported outcomes in polymyalgia rheumatica. J. Rheumatol. 39, 795\u2013803 (2012).","journal-title":"J. Rheumatol."},{"key":"1379_CR147","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1136\/annrheumdis-2021-221126","volume":"81","author":"M Bonelli","year":"2022","unstructured":"Bonelli, M. et al. Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2\/3 randomised controlled trial. Ann. Rheum. Dis. 81, 838\u2013844 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1379_CR148","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1001\/jama.2022.15459","volume":"328","author":"V Devauchelle-Pensec","year":"2022","unstructured":"Devauchelle-Pensec, V. et al. Effect of tocilizumab on disease activity in patients with active polymyalgia rheumatica receiving glucocorticoid therapy: a randomized clinical trial. JAMA 328, 1053\u20131062 (2022).","journal-title":"JAMA"},{"key":"1379_CR149","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1002\/art.43221","volume":"77","author":"B Chevet","year":"2025","unstructured":"Chevet, B. et al. Maintenance of remission after tocilizumab withdrawal in patients with glucocorticoid-dependent polymyalgia rheumatica. Arthritis Rheumatol. 77, 1416\u20131420 (2025).","journal-title":"Arthritis Rheumatol."},{"key":"1379_CR150","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1056\/NEJMoa2303452","volume":"389","author":"RF Spiera","year":"2023","unstructured":"Spiera, R. F. et al. Sarilumab for relapse of polymyalgia rheumatica during glucocorticoid taper. N. Engl. J. Med. 389, 1263\u20131272 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1379_CR151","doi-asserted-by":"publisher","first-page":"e544","DOI":"10.1016\/S2665-9913(25)00041-4","volume":"7","author":"V Strand","year":"2025","unstructured":"Strand, V. et al. Sarilumab in relapsing polymyalgia rheumatica: patient-reported outcomes from a phase 3, double-blind, randomised controlled trial. Lancet Rheumatol. 7, e544\u2013e553 (2025).","journal-title":"Lancet Rheumatol."},{"key":"1379_CR152","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1016\/S2665-9913(23)00032-2","volume":"5","author":"TE Bolhuis","year":"2023","unstructured":"Bolhuis, T. E., Marsman, D. E., den Broeder, A. A., den Broeder, N. & van der Maas, A. 1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trial. Lancet Rheumatol. 5, e208\u2013e214 (2023).","journal-title":"Lancet Rheumatol."},{"key":"1379_CR153","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1136\/ard-2022-223562","volume":"82","author":"L Zhang","year":"2023","unstructured":"Zhang, L. et al. Efficacy and safety of tofacitinib in patients with polymyalgia rheumatica: a phase 2 study. Ann. Rheum. Dis. 82, 722\u2013724 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"1379_CR154","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004249","volume":"20","author":"X Ma","year":"2023","unstructured":"Ma, X. et al. Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): an open-label randomized controlled trial. PLoS Med. 20, e1004249 (2023).","journal-title":"PLoS Med."},{"key":"1379_CR155","doi-asserted-by":"publisher","first-page":"e233","DOI":"10.1016\/S2665-9913(24)00270-4","volume":"7","author":"A Saraux","year":"2025","unstructured":"Saraux, A. et al. Baricitinib in early polymyalgia rheumatica (BACHELOR): a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Rheumatol. 7, e233\u2013e242 (2025).","journal-title":"Lancet Rheumatol."},{"key":"1379_CR156","doi-asserted-by":"publisher","first-page":"e728","DOI":"10.1016\/S2665-9913(23)00246-1","volume":"5","author":"A Saraux","year":"2023","unstructured":"Saraux, A. et al. Abatacept in early polymyalgia rheumatica (ALORS): a proof-of-concept, randomised, placebo-controlled, parallel-group trial. Lancet Rheumatol. 5, e728\u2013e735 (2023).","journal-title":"Lancet Rheumatol."},{"key":"1379_CR157","doi-asserted-by":"publisher","first-page":"631","DOI":"10.7326\/0003-4819-146-9-200705010-00005","volume":"146","author":"C Salvarani","year":"2007","unstructured":"Salvarani, C. et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann. Intern. Med. 146, 631\u2013639 (2007).","journal-title":"Ann. Intern. Med."},{"key":"1379_CR158","doi-asserted-by":"publisher","DOI":"10.1186\/ar3140","volume":"12","author":"F Kreiner","year":"2010","unstructured":"Kreiner, F. & Galbo, H. Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial. Arthritis Res. Ther. 12, R176 (2010).","journal-title":"Arthritis Res. Ther."},{"key":"1379_CR159","doi-asserted-by":"publisher","unstructured":"Kitching, A. R., Hill, C. & Quincey, V. Proc. 22nd International Vasculitis Workshop https:\/\/doi.org\/10.5281\/zenodo.18693153 (2026).","DOI":"10.5281\/zenodo.18693153"},{"key":"1379_CR160","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4081\/reumatismo.2020.1268","volume":"72","author":"N Ughi","year":"2020","unstructured":"Ughi, N. et al. The Italian Society of Rheumatology clinical practice guidelines for the management of polymyalgia rheumatica. Reumatismo 72, 1\u201315 (2020).","journal-title":"Reumatismo"},{"key":"1379_CR161","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1093\/rheumatology\/kep303a","volume":"49","author":"B Dasgupta","year":"2010","unstructured":"Dasgupta, B. et al. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology 49, 186\u2013190 (2010).","journal-title":"Rheumatology"},{"key":"1379_CR162","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-024-00422-6","volume":"8","author":"S Tengesdal","year":"2024","unstructured":"Tengesdal, S., Diamantopoulos, A. P., Brekke, L. K., Besada, E. & Myklebust, G. Norwegian Society of Rheumatology recommendations on diagnosis and treatment of patients with polymyalgia rheumatica: a narrative review. BMC Rheumatol. 8, 58 (2024).","journal-title":"BMC Rheumatol."},{"key":"1379_CR163","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1136\/ard.2003.011379","volume":"63","author":"BF Leeb","year":"2004","unstructured":"Leeb, B. F. & Bird, H. A. A disease activity score for polymyalgia rheumatica. Ann. Rheum. Dis. 63, 1279\u20131283 (2004).","journal-title":"Ann. Rheum. Dis."},{"key":"1379_CR164","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1053\/sarh.2000.8366","volume":"30","author":"F Cantini","year":"2000","unstructured":"Cantini, F. et al. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin. Arthritis Rheum. 30, 17\u201324 (2000).","journal-title":"Semin. Arthritis Rheum."},{"key":"1379_CR165","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nrrheum.2012.97","volume":"8","author":"C Salvarani","year":"2012","unstructured":"Salvarani, C., Pipitone, N., Versari, A. & Hunder, G. G. G. Clinical features of polymyalgia rheumatica and giant cell arteritis. Nat. Rev. Rheumatol. 8, 509\u2013521 (2012).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1379_CR166","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/cen.14405","volume":"94","author":"R Sagar","year":"2021","unstructured":"Sagar, R. et al. Evaluating tertiary adrenal insufficiency in rheumatology patients on long-term systemic glucocorticoid treatment. Clin. Endocrinol. 94, 361\u2013370 (2021).","journal-title":"Clin. Endocrinol."},{"key":"1379_CR167","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/art.1780390110","volume":"39","author":"C Salvarani","year":"1996","unstructured":"Salvarani, C., Gabriel, S. & Hunder, G. G. Distal extremity swelling with pitting edema in polymyalgia rheumatica. Report on nineteen cases. Arthritis Rheum. 39, 73\u201380 (1996).","journal-title":"Arthritis Rheum."},{"key":"1379_CR168","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1002\/1529-0131(199807)41:7<1221::AID-ART12>3.0.CO;2-W","volume":"41","author":"C Salvarani","year":"1998","unstructured":"Salvarani, C. et al. Distal musculoskeletal manifestations in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum. 41, 1221\u20131226 (1998).","journal-title":"Arthritis Rheum."},{"key":"1379_CR169","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1093\/rheumatology\/kead189","volume":"63","author":"E De Miguel","year":"2024","unstructured":"De Miguel, E. et al. Prevalence and characteristics of subclinical giant cell arteritis in polymyalgia rheumatica. Rheumatology 63, 158\u2013164 (2024).","journal-title":"Rheumatology"},{"key":"1379_CR170","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1136\/ard-2023-224768","volume":"83","author":"E De Miguel","year":"2023","unstructured":"De Miguel, E. et al. Subclinical giant cell arteritis increases the risk of relapse in polymyalgia rheumatica. Ann. Rheumatic Dis. 83, 335\u2013341 (2023).","journal-title":"Ann. Rheumatic Dis."},{"key":"1379_CR171","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1093\/rheumatology\/keae531","volume":"64","author":"S Cowley","year":"2025","unstructured":"Cowley, S., Harkins, P., Kirby, C., Conway, R. & Kane, D. Real-world outcomes of a dedicated fast-track polymyalgia rheumatica clinic. Rheumatology 64, 3006\u20133011 (2025).","journal-title":"Rheumatology"},{"key":"1379_CR172","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1093\/rheumatology\/kead450","volume":"63","author":"AK Hemmig","year":"2024","unstructured":"Hemmig, A. K. et al. Prior polymyalgia rheumatica is associated with sonographic vasculitic changes in newly diagnosed patients with giant cell arteritis. Rheumatology 63, 1523\u20131527 (2024).","journal-title":"Rheumatology"},{"key":"1379_CR173","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1002\/art.1780401022","volume":"40","author":"SE Gabriel","year":"1997","unstructured":"Gabriel, S. E., Sunku, J., Salvarani, C., O\u2019Fallon, W. M. & Hunder, G. G. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum. 40, 1873\u20131878 (1997).","journal-title":"Arthritis Rheum."},{"key":"1379_CR174","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2147\/OARRR.S213964","volume":"11","author":"E Hoon","year":"2019","unstructured":"Hoon, E., Ruediger, C., Gill, T. K., Black, R. J. & Hill, C. L. A qualitative study of patient perspectives related to glucocorticoid therapy in polymyalgia rheumatica and giant cell arteritis. Open Access Rheumatol. 11, 189\u2013198 (2019).","journal-title":"Open Access Rheumatol."},{"key":"1379_CR175","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003432","volume":"17","author":"M Pujades-Rodriguez","year":"2020","unstructured":"Pujades-Rodriguez, M., Morgan, A. W., Cubbon, R. M. & Wu, J. Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: a population-based cohort study. PLoS Med. 17, e1003432 (2020).","journal-title":"PLoS Med."},{"key":"1379_CR176","doi-asserted-by":"publisher","first-page":"4455","DOI":"10.1093\/rheumatology\/keac050","volume":"61","author":"SE Sattui","year":"2022","unstructured":"Sattui, S. E. et al. Prevalence of frailty in patients with polymyalgia rheumatica and association with health-related quality of life, cognition and sarcopenia. Rheumatology 61, 4455\u20134464 (2022).","journal-title":"Rheumatology"},{"key":"1379_CR177","doi-asserted-by":"publisher","first-page":"5834","DOI":"10.1093\/rheumatology\/keaf375","volume":"64","author":"JL Leung","year":"2025","unstructured":"Leung, J. L. et al. Changes to physical function and body composition during the first 2\u2009years of polymyalgia rheumatica. Rheumatology 64, 5834\u20135843 (2025).","journal-title":"Rheumatology"},{"key":"1379_CR178","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.05.081","volume":"84","author":"F Buttgereit","year":"2025","unstructured":"Buttgereit, F. et al. OP0058 Effects of clofutriben, a selective 11\u00df-hydroxysteroid dehydrogenase type 1 inhibitor, on efficacy and toxicity of prednisolone in patients with polymyalgia rheumatica. Ann. Rheumatic Dis. 84, 51 (2025).","journal-title":"Ann. Rheumatic Dis."},{"key":"1379_CR179","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1136\/ard-2022-223367","volume":"82","author":"C Dejaco","year":"2023","unstructured":"Dejaco, C. et al. The provisional OMERACT ultrasonography score for giant cell arteritis. Ann. Rheum. Dis. 82, 556\u2013564 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"1379_CR180","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3899\/jrheum.200248","volume":"48","author":"H Twohig","year":"2021","unstructured":"Twohig, H. et al. Outcomes measured in polymyalgia rheumatica and measurement properties of instruments considered for the OMERACT core outcome set: a systematic review. J. Rheumatol. 48, 883\u2013893 (2021).","journal-title":"J. Rheumatol."},{"key":"1379_CR181","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkae003","volume":"8","author":"CE Owen","year":"2024","unstructured":"Owen, C. E. et al. Characterising polymyalgia rheumatica on whole-body 18F-FDG PET\/CT: an atlas. Rheumatol. Adv. Pract. 8, rkae003 (2024).","journal-title":"Rheumatol. Adv. Pract."},{"key":"1379_CR182","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1093\/rheumatology\/keaa646","volume":"60","author":"D Camellino","year":"2021","unstructured":"Camellino, D., Duftner, C. & Dejaco, C. New insights into the role of imaging in polymyalgia rheumatica. Rheumatology 60, 1016\u20131033 (2021).","journal-title":"Rheumatology"},{"key":"1379_CR183","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.ard.2025.01.018","volume":"84","author":"S Monti","year":"2025","unstructured":"Monti, S. et al. The giant cell arteritis (GCA) ultrasound score (OGUS) at diagnosis and after initial treatment predicts future relapses in GCA patients: results of a multicentre prospective study. Ann. Rheum. Dis. 84, 823\u2013832 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"1379_CR184","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1093\/rheumatology\/keae208","volume":"63","author":"L Moreel","year":"2024","unstructured":"Moreel, L. et al. Prevalence, characteristics, and outcome of subclinical vasculitis in polymyalgia rheumatica: a retrospective cohort study. Rheumatology 63, 3331\u20133336 (2024).","journal-title":"Rheumatology"}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01379-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01379-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01379-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:02:32Z","timestamp":1782432152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01379-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":184,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1379"],"URL":"https:\/\/doi.org\/10.1038\/s41584-026-01379-1","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"17 April 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.M. has received consulting fees and\/or speaker honoraria from AbbVie, Amgen, AstraZeneca, CSL Vifor and GSK, and has received royalties from UpToDate. K.J.W. has received clinical trial support from BMS and consulting fees from Amgen, AstraZeneca and Sanofi. C.D. has received consulting fees and\/or speaker honoraria from AbbVie, Fresenius, Janssen, Novartis, Sanofi and Sparrow. M.C.C. has received consulting fees from AbbVie, Alexion, AstraZeneca, Boehringer-Ingelheim, CSL-Vifor, GSK, Novartis and Royalty Pharma, and royalties from UpToDate. B.H. has received honoraria for advisory services from AbbVie, Alexion, AstraZeneca, Boehringer, BMS, Chugai, CSL Vifor, GSK, Novartis, Sanofi and Visterra, and honoraria for lectures from AbbVie, AstraZeneca, Boehringer, GSK, Pfizer, Medac, Novartis and Vifor Fresenius Medical Care Renal Pharma. A.W.M. has received consultancy fees payable to her institution from AstraZeneca, CSL Vifor, Glaxo Smith Kline, Roche\/Chugai and Sanofi\/Regeneron, outside the submitted work, and research and educational funding from Kiniksa Pharmaceuticals and Roche\/Chugai, outside the submitted work. S.C. declares no competing interests. C.S. has received consulting fees and\/or speaker honoraria from AbbVie, Amgen, AstraZeneca, Boehringer, CSL Vifor, GSK and Novartis, and royalties from UpToDate.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}